Mustang Leads Fortress's CAR-T Ambitions Of Monstrous Proportions

26 Jul 2017

Emerging Company Profile: The two-year-old company combines the Fortress Biotech model with City of Hope's broad expertise in CAR-T technology, plus leadership from a pioneer in the space.

The term "Frankenstein's monster" typically is not a positive way to describe an enterprise, but it may be an apt metaphor for Mustang Bio Inc., a Fortress Biotech Inc. portfolio company.

Mustang combines that umbrella organization's basic business model with significant intellectual property rights to City of Hope technology in the chimeric antigen receptor engineered T-cell (CAR-T) space

Mustang Bio Inc.

Location: New York

R&D Focus: Chimeric antigen receptor engineered T-cell (CAR-T) therapies for cancer.

Disease Area: Oncology

Founding Date: March 2015

Founders: Coronado Biosciences (now Fortress Biotech); Lindsay Rosenwald, Stephen Forman, Christine Brown

Employees: Three, plus Fortress Biotech personnel

Financing To Date: $94

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Eisai Forecasts 73% Leqembi Sales Rise In FY25 As Demand Expands

16 May 2025

• By Mandy Jackson

Eisai spent most of its FY24 earnings call discussing plans for growing sales of Biogen-partnered Alzheimer’s drug Leqembi from JPY44.3bn ($304.1m) to JPY76.5bn ($525.1m) in FY25.

UK-India FTA Could Offer ‘Significant Benefits’ For Generics, Biosimilars

15 May 2025

• By Dave Wallace

A free trade agreement between the UK and India could offer “significant benefits for the generic and biosimilar sectors,” Medicines UK believes. The off-patent industry association has also suggested further avenues for collaboration between the two governments.

Will Other Major MASH Deals Follow GSK/Boston Pharma?

15 May 2025

• By Joseph Haas

GSK’s $1.2bn payout for Boston Pharma’s efimosfermin is the first billion-dollar-plus MASH deal in nearly nine years, but several other advanced MASH programs could be positioned for takeout.

Most Favored Nation Policy ‘Lazy, Misguided,’ But US Price Reforms Politically ‘Inevitable’

15 May 2025

• By Cathy Kelly

Policy experts and pharma executives react to President Trump’s executive order on “equalizing” drug prices between the US and comparable nations at the ISPOR 2025 conference.

Most Favored Nation Policy ‘Lazy, Misguided,’ But US Price Reforms Politically ‘Inevitable’

15 May 2025

• By Cathy Kelly

Policy experts and pharma executives react to President Trump’s executive order on “equalizing” drug prices between the US and comparable nations at the ISPOR 2025 conference.